Axsome Therapeutics (AXSM) Cost of Revenue (2022 - 2026)

Axsome Therapeutics has disclosed Cost of Revenue across 5 years of filings, most recently posting $14.7 million for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $14.7 million, up 50.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $52.4 million (up 42.45% YoY), and the FY2025 annual result was $47.5 million, up 42.56% from the prior year.
• Cost of Revenue came in at $14.7 million for Q1 2026 at Axsome Therapeutics, up from $12.3 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $14.7 million in Q1 2026 to a low of $983000.0 in Q2 2022.
• The 5-year median for Cost of Revenue is $7.8 million (2023), against an average of $7.9 million.
• Across the five-year window, Cost of Revenue soared 367.85% in 2023 and declined 16.66% in 2024, its largest moves.
• Axsome Therapeutics' Cost of Revenue stood at $2.3 million in 2022, then surged by 222.04% to $7.4 million in 2023, then jumped by 42.5% to $10.5 million in 2024, then rose by 17.26% to $12.3 million in 2025, then advanced by 19.43% to $14.7 million in 2026.
• The last three Cost of Revenue figures came in at $14.7 million (Q1 2026), $12.3 million (Q4 2025), and $11.9 million (Q3 2025), per Business Quant data.